Further Italian Drug Price Cut Possible In June

13 February 1995

A new drug price cut in Italy is not to be excluded, says a Budget Ministry official, who points to June as a possible new deadline. The 2.5% price cut envisaged for January 1 actually took effect at the end of January, which could necessitate further cuts before summer, in order to comply with the cuts in state drugs spending set by the 1995 finance Act.

The one-month delay in adopting the price reduction provision means that there will be a 30 billion lire ($12.6 million) gap in the forecast savings by year-end. Moreover, according to the Budget Ministry official, the state's provisional accounts tend to overestimate the effects expected from the second 2.5% price cut which is to come into effect within a few days. This new cut affects only products of companies reporting a 10% turnover increase last year.

The 450 billion lire ($279.1 million) overall savings in pharmaceutical expenditures written into the 1995 finance law are also threatened by a third factor. According to the Ministry official, the provision, which calls for manufacturers to put on the shelf "optimal" packaging, may not be as effective as believed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight